tbuckley/cabot-search huggingface dataset:
Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment
Authors: Josanne Sophia de Maar, Alexandros Marios Sofias, Tiffany Porta Siegel, Rob J. Vreeken, Chrit Moonen, Clemens Bos, Roel Deckers
Journal: Theranostics (2020)

Genetic and phenotypic tumour heterogeneity is an important cause of therapy resistance.Moreover, non-uniform spatial drug distribution in cancer treatment may cause pseudo-resistance, meaning that a treatment is ineffective because the drug does not reach its target at sufficient concentrations.Together with tumour heterogeneity, non-uniform drug distribution causes "therapy heterogeneity": a spatially heterogeneous treatment effect.Spatial heterogeneity in drug distribution occurs on all scales ranging from interpatient differences to intratumour differences on tissue or cellular scale.Nanomedicine aims to improve the balance between efficacy and safety of drugs by targeting drug-loaded nanoparticles specifically to tumours.Spatial heterogeneity in nanoparticle and payload distribution could be an important factor that limits their efficacy in patients.Therefore, imaging spatial nanoparticle distribution and imaging the tumour environment giving rise to this distribution could help understand (lack of) clinical success of nanomedicine.Imaging the nanoparticle, drug and tumour environment can lead to improvements of new nanotherapies, increase understanding of underlying mechanisms of heterogeneous distribution, facilitate patient selection for nanotherapies and help assess the effect of treatments that aim to reduce heterogeneity in nanoparticle distribution.In this review, we discuss three groups of imaging modalities applied in nanomedicine research: non-invasive clinical imaging methods (nuclear imaging, MRI, CT, ultrasound), optical imaging and mass spectrometry imaging.Because each imaging modality provides information at a different scale and has its own strengths and weaknesses, choosing wisely and combining modalities will lead to a wealth of information that will help bring nanomedicine forward.
Trends in Anogenital Wart Diagnoses in Connecticut, 2013-2017
Authors: Anthony E. Yakely, Linda M. Niccolai, Carlos R. Oliveira
Journal: JAMA Network Open (2020)

For the primary analysis, we estimated the overall percentage changes in AGW diagnoses and the mean percentage change with 95% CIs and Cochran-Armitage tests for 6-month intervals.Analyses were further stratified by age, sex, race, insurance status, and vaccine eligibility by birth year.P values for comparison of incidence rates (2-sided) and trends (1-sided) were calculated using Poisson regression and Cochran-Armitage tests, with P < .05considered statistically significant for all comparisons.Analyses were conducted using SAS statistical software version 9.4 (SAS Institute) and Joinpoint statistical software desktop version 4.7.0.
Sixty seconds on . . . Goop
Authors: Abi Rimmer
Journal: BMJ (2020)

No, we’re not talking about the contents of a week old wound dressing. Goop is a wellness and lifestyle company founded by actress Gwyneth Paltrow (of Shakespeare in Love and Contagion fame). She’s referred to on the Goop website as “GP.”

Not as far as we know, however her website does sell the “Goop medicine bag”1 for £76 (€90; $100), which contains eight crystals including smoky quartz, red jasper, and citrine.

So does Simon Stevens, it turns out. Speaking about …
Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035
Authors: Melina Arnold, Jin Young Park, M Constanza Camargo, Nuno Lunet, David Forman, Isabelle Soerjomataram
Journal: Gut (2020)

Objectives The incidence of gastric cancer continues to decrease globally, approaching levels that in some populations could define it as a rare disease. To explore this on a wider scale, we predict its future burden in 34 countries with long-standing population-based data. Methods Data on gastric cancer incidence by year of diagnosis, sex and age were extracted for 92 cancer registries in 34 countries included in Cancer Incidence in Five Continents Plus. Numbers of new cases and age-standardised incidence rates (ASR per 100 000) were predicted up to 2035 by fitting and extrapolating age–period–cohort models. Results Overall gastric cancer incidence rates are predicted to continue falling in the future in the majority of countries, including high-incidence countries such as Japan (ASR 36 in 2010 vs ASR 30 in 2035) but also low-incidence countries such as Australia (ASR 5.1 in 2010 vs ASR 4.6 in 2035). A total of 16 countries are predicted to fall below the rare disease threshold (defined as 6 per 100 000 person-years) by 2035, while the number of newly diagnosed cases remains high and is predicted to continue growing. In contrast, incidence increases were seen in younger age groups (below age 50 years) in both low-incidence and high-incidence populations. Conclusions While gastric cancer is predicted to become a rare disease in a growing number of countries, incidence levels remain high in some regions, and increasing risks have been observed in younger generations. The predicted growing number of new cases highlights that gastric cancer remains a major challenge to public health on a global scale.
Risk for Cancer in Patients with Barrett Esophagus
Authors: Nicholas J Shaheen
Journal: Annals of Internal Medicine (2000)

Summaries for Patients18 April 2000Risk for Cancer in Patients with Barrett EsophagusSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-8-200004180-00036 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Barrett esophagus is a condition in which the lining of the esophagus (the tube that connects the mouth to the stomach) becomes abnormal. This change may occur when stomach contents, including acid, rise up into the esophagus, a condition known as gastroesophageal reflux disease (GERD). The only way to know if a person has Barrett changes is to look at the esophagus with a special instrument that is passed through the mouth into the esophagus and stomach (a procedure called esophagogastroduodenoscopy, or EGD). Using this instrument, the doctor ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus.”. It is in the 18 April 2000 issue of Annals of Internal Medicine (volume 132, pages 612-620). The authors are R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, and B.J. Reid.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus Rebecca E. Rudolph , Thomas L. Vaughan , Barry E. Storer , Rodger C. Haggitt , Peter S. Rabinovitch , Douglas S. Levine , and Brian J. Reid Metrics Cited byPrevalence of constipation in adults with obesity class II and III and associated factors 18 April 2000Volume 132, Issue 8Page: 612KeywordsAneuploidyCellsDecision makingEsophageal cancerEsophagogastroduodenoscopyEsophagusGastroesophageal reflux diseaseMouthRisk managementStomach ePublished: 15 August 2000 Issue Published: 18 April 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
Genome-wide In Vivo CNS Screening Identifies Genes that Modify CNS Neuronal Survival and mHTT Toxicity
Authors: Mary H. Wertz, Mollie R. Mitchem, S. Sebastian Pineda, Lea J. Hachigian, Hyeseung Lee, Vanessa Lau, Alex Powers, Ruth Kulicke, Gurrein K. Madan, Medina Colic, Martine Therrien, Amanda Vernon, Victoria F. Beja-Glasser, Mudra Hegde, Fan Gao, Manolis Kellis, Traver Hart, John G. Doench, Myriam Heiman
Journal: Neuron (2020)
Association of soy and fermented soy product intake with total and cause specific mortality: prospective cohort study
Authors: Ryoko Katagiri, Norie Sawada, Atsushi Goto, Taiki Yamaji, Motoki Iwasaki, Mitsuhiko Noda, Hiroyasu Iso, Shoichiro Tsugane
Journal: BMJ (2020)

Abstract Objective To investigate the association between several types of soy products and all cause and cause specific mortality. Design Population based cohort study. Setting Japan Public Health Centre-based Prospective Study, which includes 11 public health centre areas in Japan. Participants 92 915 participants (42 750 men and 50 165 women) aged 45 to 74 years. Exposures Intake of total soy products, fermented soy products (natto and miso), non-fermented soy products, and tofu from a five year survey questionnaire. Main outcome measures All cause and cause specific mortality (cancer, total cardiovascular disease, heart disease, cerebrovascular disease, respiratory disease, and injury) obtained from residential registries and death certificates. Results During 14.8 years of follow-up, 13 303 deaths were identified. In the multivariable adjusted models, intake of total soy products was not significantly associated with total mortality. Compared with the lowest fifth of total soy product intake, the hazard ratios in the highest fifth were 0.98 (95% confidence interval 0.91 to 1.06, P trend =0.43) in men and 0.98 (0.89 to 1.08, P trend =0.46) in women. Intake of fermented soy products was inversely associated with all cause mortality in both sexes (highest versus lowest fifth: 0.90 (0.83 to 0.97), P trend =0.05 in men, and 0.89 (0.80 to 0.98), P trend =0.01 in women). Natto showed significant and inverse associations with total cardiovascular disease related mortality in both sexes. Conclusions In this study a higher intake of fermented soy was associated with a lower risk of mortality. A significant association between intake of total soy products and all cause mortality was not, however, observed. The findings should be interpreted with caution because the significant association of fermented soy products might be attenuated by unadjusted residual confounding.
Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant—Reply
Authors: Alex C. Spyropoulos, Sam Schulman, James D. Douketis
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Richard Alpert (Ram Dass): Harvard psychologist who experimented with psychedelic drugs and became one of America’s most prominent and respected spiritual leaders
Authors: Rebecca Wallersteiner
Journal: BMJ (2020)

Credit: Dassima Kathleen Murphy

Nothing in Richard Alpert’s early life could have predicted that he would come to embody the spirit of the psychedelic 1960s. He was born in Boston, Massachusetts, the youngest of three sons, to George and Gertrude (Levin) Alpert. His father, a prominent lawyer in Boston, was a founder of Brandeis University and went on to become president of the New York and New Haven Railroad. Alpert had a bar mitzvah but did not show much interest in religion in his youth. He attended Williston Northampton School, graduating in 1948. His father wanted him to become a doctor, but Alpert failed to get into medical school and instead studied psychology, gaining a doctorate at Stanford University.

On moving to Harvard in 1961, he taught and researched at the department of social relations and the graduate school of education and was popular with his students. It was at Harvard that he befriended the charismatic Timothy Leary, a countercultural icon, who was lecturing in clinical psychology. Continuing his early work at the University of California, Berkeley, Leary was carrying out research on psilocybin, the main psychoactive ingredient in some species of mushrooms, to see if they could be beneficial in the clinical treatment of schizophrenia. He invited some friends, including Alpert and the poet Allen Ginsberg, to experiment with 10 mg doses of psilocybin. Alpert later related that the transcendent effect of psychedelic drugs had caused him to question consciousness and the very basis of his life. He collaborated on Leary’s Harvard psilocybin project, giving the drug, and later LSD, to students, ministers, musicians, and prisoners. While …
10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer
Authors: A. Prat, M.C. Cheang, M. Martín, E. Carrasco, R. Caballero, S. Tyldesley, K. Gelmon, P.S. Bernard, T.O. Nielsen, C.M. Perou
Journal: Annals of Oncology (2012)
Recommendations for Cardiovascular Health and Disease Surveillance for 2030 and Beyond: A Policy Statement From the American Heart Association
Authors: Véronique L. Roger, Stephen Sidney, Amy L. Fairchild, Virginia J. Howard, Darwin R. Labarthe, Christina M. Shay, A. Colby Tiner, Laurie P. Whitsel, Wayne D. Rosamond
Journal: Circulation (2020)

The release of the American Heart Association's 2030 Impact Goal and associated metrics for success underscores the importance of cardiovascular health and cardiovascular disease surveillance systems for the acquisition of information sufficient to support implementation and evaluation. The aim of this policy statement is to review and comment on existing recommendations for and current approaches to cardiovascular surveillance, identify gaps, and formulate policy implications and pragmatic recommendations for transforming surveillance of cardiovascular disease and cardiovascular health in the United States. The development of community platforms coupled with widespread use of digital technologies, electronic health records, and mobile health has created new opportunities that could greatly modernize surveillance if coordinated in a pragmatic matter. However, technology and public health and scientific mandates must be merged into action. We describe the action and components necessary to create the cardiovascular health and cardiovascular disease surveillance system of the future, steps in development, and challenges that federal, state, and local governments will need to address. Development of robust policies and commitment to collaboration among professional organizations, community partners, and policy makers are critical to ultimately reduce the burden of cardiovascular disease and improve cardiovascular health and to evaluate whether national health goals are achieved.
Abstract 9549: Effects of Canagliflozin in Patients With Type 2 Diabetes and Chronic Heart Failure: A Randomized Clinical Trial (CANDLE)
Authors: Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Masataka Sata, Shinichiro Ueda, Jun-ichi Oyama, Masafumi Kitakaze, Toyoaki Murohara, Koichi Node
Journal: Circulation (2019)

Introduction: Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure-related outcomes in patients with type 2 diabetes (T2D). However, little is known about the safety ...
Nothing New Under the Sun
Authors: Charlotte Matthews
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CEST MRI detectable liposomal hydrogels for multiparametric monitoring in the brain at 3T
Authors: Xiongqi Han, Jianpan Huang, Anthea K.W. To, Joseph H.C. Lai, Peng Xiao, Ed X. Wu, Jiadi Xu, Kannie W.Y. Chan
Journal: Theranostics (2020)

Adjuvant treatment using local drug delivery is applied in treating glioblastoma multiforme (GBM) after tumor resection.However, there are no non-invasive imaging techniques available for tracking the compositional changes of hydrogel-based drug treatment.Methods: We developed Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST MRI) detectable and injectable liposomal hydrogel to monitor these events in vivo at 3T clinical field.Mechanical attributes of these hydrogels and their in vitro and in vivo CEST imaging properties were systematically studied. Results:The MRI detectable hydrogels were capable of generating multiparametric readouts for monitoring specific components of the hydrogel matrix simultaneously and independently.Herein, we report, for the first time, CEST contrast at -3.4 ppm provides an estimated number of liposomes and CEST contrast at 5 ppm provides an estimated amount of encapsulated drug.CEST contrast decreased by 1.57% at 5 ppm, while the contrast at -3.4 ppm remained constant over 3 d in vivo, demonstrating different release kinetics of these components from the hydrogel matrix.Furthermore, histology analysis confirmed that the CEST contrast at -3.4 ppm was associated with liposome concentrations.Conclusion: This multiparametric CEST imaging of individual compositional changes in liposomal hydrogels, formulated with clinical-grade materials at 3T and described in this study, has the potential to facilitate the refinement of adjuvant treatment for GBM.
Immunophenotypic and Proteomic Characterization of Cord Blood (CB) CD56dim Versus Peripheral Blood (PB) CD56dim NK Cells.
Authors: Evan Shereck, Nancy Day, Catherine McGuinn, Prakash Satwani, Carmella van de Ven, Janet Ayello, David Crockett, Ronald J. Wapner, Kojo Elenitoba-Johnson, Megan Lim, Mitchell S. Cairo
Journal: Blood (2007)
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion
Authors: Shin-Young Park, Alessandro Matte, Yookyung Jung, Jina Ryu, Wilson Babu Anand, Eun-Young Han, Min Liu, Carmine Carbone, Davide Melisi, Takashi Nagasawa, Joseph J. Locascio, Charles P. Lin, Leslie E. Silberstein, Lucia De Franceschi
Journal: Blood (2020)
Effect of a Virtual Patient Navigation Program on Behavioral Health Admissions in the Emergency Department
Authors: Jason Roberge, Andrew McWilliams, Jing Zhao, William E. Anderson, Timothy Hetherington, Christine Zazzaro, Elisabeth Hardin, Amy Barrett, Manuel Castro, Margaret E. Balfour, James Rachal, Constance Krull, Wayne Sparks
Journal: JAMA Network Open (2020)

<h3>Importance</h3> The number of patients presenting to emergency departments (EDs) for psychiatric care continues to increase. Psychiatrists often make a conservative recommendation to admit patients because robust outpatient services for close follow-up are lacking. <h3>Objective</h3> To assess whether the availability of a 45-day behavioral health–virtual patient navigation program decreases hospitalization among patients presenting to the ED with a behavioral health crisis or need. <h3>Design, Setting, and Participants</h3> This randomized clinical trial enrolled 637 patients who presented to 6 EDs spanning urban and suburban locations within a large integrated health care system in North Carolina from June 12, 2017, through February 14, 2018; patients were followed up for up to 45 days. Eligible patients were aged 18 years or older, with a behavioral health crisis and a completed telepsychiatric ED consultation. The availability of the behavioral health–virtual patient navigation intervention was randomly allocated to specific days (Monday through Friday from 7amto 7pm) so that, in a 2-week block, there were 5 intervention days and 5 usual care days; 323 patients presented on days when the program was offered, and 314 presented on usual care days. Data analysis was performed from March 7 through June 13, 2018, using an intention-to-treat approach. <h3>Interventions</h3> The behavioral health–virtual patient navigation program included video contact with a patient while in the ED and telephonic outreach 24 to 72 hours after discharge and then at least weekly for up to 45 days. <h3>Main Outcomes and Measures</h3> The primary outcome was the conversion of an ED encounter to hospital admission. Secondary outcomes included 45-day follow-up encounters with a self-harm diagnosis and postdischarge acute care use. <h3>Results</h3> Among 637 participants, 358 (56.2%) were men, and the mean (SD) age was 39.7 (16.6) years. The conversion rates were 55.1% (178 of 323) in the intervention group vs 63.1% (198 of 314) in the usual care group (odds ratio, 0.74; 95% CI, 0.54-1.02;<i>P</i> = .06). The percentage of patient encounters with follow-up encounters having a self-harm diagnosis was significantly lower in the intervention group compared with the usual care group (36.8% [119 of 323] vs 45.5% [143 of 314];<i>P</i> = .03). <h3>Conclusions and Relevance</h3> Although the primary result did not reach statistical significance, there is a strong signal of potential positive benefit in an area that lacks evidence, suggesting that there should be additional investment and inquiry into virtual behavioral health programs. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT03204643